Last reviewed · How we verify
botulinum toxin Type A (44U)
Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction. Used for Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy, Cervical dystonia.
At a glance
| Generic name | botulinum toxin Type A (44U) |
|---|---|
| Also known as | BOTOX® |
| Sponsor | Allergan |
| Drug class | Neuromodulator |
| Target | Acetylcholine release |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting acetylcholine release, botulinum toxin Type A (44U) reduces muscle spasms and contractions, providing therapeutic benefits in various indications.
Approved indications
- Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy
- Cervical dystonia
Common side effects
- Dry mouth
- Headache
- Injection site pain
- Fatigue
Key clinical trials
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines (PHASE3)
- BOTOX® in the Treatment of Upper Facial Lines in Japan (PHASE3)
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- botulinum toxin Type A (44U) CI brief — competitive landscape report
- botulinum toxin Type A (44U) updates RSS · CI watch RSS
- Allergan portfolio CI